Drug profile · INN
lazertinib mesilate hydrate
LAZCLUZE
lazertinib mesilate hydrate (LAZCLUZE) is a epidermal growth factor receptor erbb1 inhibitor.
PMDA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — lazertinib mesilate hydrate
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.78
Quick answer
lazertinib mesilate hydrate (LAZCLUZE) is a epidermal growth factor receptor erbb1 inhibitor.
Key facts
INN lazertinib mesilate hydrate
Brand LAZCLUZE
Mechanism Epidermal growth factor receptor erbB1 inhibitor
Target Epidermal growth factor receptor
Mechanism of action
Epidermal growth factor receptor erbB1 inhibitor
Primary target: Epidermal growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is lazertinib mesilate hydrate?
lazertinib mesilate hydrate (LAZCLUZE) is a epidermal growth factor receptor erbb1 inhibitor.
What is the brand name for lazertinib mesilate hydrate?
LAZCLUZE is a marketed brand name for lazertinib mesilate hydrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.